TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24162333

Group type: EXPERIMENTAL
Intervention: Adolescents and young adults (AYAs) aged 16-29 years
Number of subjects: 1524

Group type: COMPARATOR
Intervention: All age groups
Number of subjects: 1524
Study: 24162791

Group type: EXPERIMENTAL
Intervention: Horse antithymocyte globulin
Number of subjects: 95

Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin
Number of subjects: 95
Study: 24163067

Group type: EXPERIMENTAL
Intervention: 50-Hz electromagnetic fields with strengths of up to 30 kV·m⁻¹ and 2.55 mT
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Programming to maximum sensitivity
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Comparison of right atrial/right ventricular interferences
Number of subjects: 110
Study: 24163385

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory II scores
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Number of MSIMI-positive tasks
Number of subjects: 283
Study: 24164320

Group type: EXPERIMENTAL
Intervention: 1-year gluten-free diet (GFD) in celiac patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Active celiac disease (ACD) patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Diarrhea-predominant irritable bowel syndrome (IBS-d) patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study: 24164965

Group type: EXPERIMENTAL
Intervention: Obese adolescents (n=37)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Obese-NGT adolescents (n=22)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Obese-IGR adolescents (n=15)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Lean adolescents (n=14)
Number of subjects: 51
Study: 24165027

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 5279

Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 5279

Group type: EXPERIMENTAL
Intervention: Abdominal hysterectomy (AH)
Number of subjects: 5279

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 5279
Study: 24165173

Group type: EXPERIMENTAL
Intervention: Anidulafungin (100 mg once daily after a loading dose of 200 mg on the first day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 20
Study: 24166490

Group type: EXPERIMENTAL
Intervention: Vitamin E serum levels (vit E/chol)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: History of coronary heart disease
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Serum vit E/chol quartiles
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: HAS-BLED scores
Number of subjects: 566
Study: 24166890

Group type: EXPERIMENTAL
Intervention: Continued medical therapy (CMT) for a mean of 7.1 months
Number of subjects: 31
Study: 24167727

Group type: EXPERIMENTAL
Intervention: Computer-controlled pressure algometry on the vastus lateralis muscle
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Computer-controlled pressure algometry
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hypertonic saline injections
Number of subjects: 28
Study: 24168104

Group type: EXPERIMENTAL
Intervention: Platinum regimens
Number of subjects: 3508

Group type: EXPERIMENTAL
Intervention: Non-platinum regimens
Number of subjects: 3508

Group type: EXPERIMENTAL
Intervention: Regimens with bevacizumab
Number of subjects: 3508

Group type: EXPERIMENTAL
Intervention: Investigational regimens
Number of subjects: 3508

Group type: EXPERIMENTAL
Intervention: Best supportive care
Number of subjects: 3508

Group type: EXPERIMENTAL
Intervention: Severe adverse events (AEs)
Number of subjects: 3508
Study: 24168522

Group type: EXPERIMENTAL
Intervention: EEG-neurofeedback treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo-neurofeedback treatment
Number of subjects: 41
Study: 24170105

Group type: EXPERIMENTAL
Intervention: Total 25(OH)D
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Bioavailable 25(OH)D/Total 25(OH)D
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: VDBP
Number of subjects: 47
Study: 24170283

Group type: EXPERIMENTAL
Intervention: Dacryoliths
Number of subjects: 86
Study: 24170610

Group type: EXPERIMENTAL
Intervention: GDC-0449 150 mg/day (days 1-28, 28-day cycle)
Number of subjects: 45
Study: 24171147

Group type: EXPERIMENTAL
Intervention: Naltrexone 32 mg/d and Bupropion 360 mg/d (NB32) with dietary and behavioral counseling
Number of subjects: 25
Study: 24171941

Group type: EXPERIMENTAL
Intervention: Positive imagery cognitive bias modification (CBM)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combined positive imagery CBM and internet cognitive behavioural therapy (iCBT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control CBM and iCBT
Number of subjects: 29
Study: 24172190

Group type: EXPERIMENTAL
Intervention: Right atrium
Number of subjects: 22

Group type: COMPARATOR
Intervention: Left atrium
Number of subjects: 22
Study: 24172304

Group type: EXPERIMENTAL
Intervention: 6-wk energy-restricted, high-protein diet
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 6-wk weight maintenance
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline characteristics (plasma insulin, IL-6, adipose tissue inflammation, Lactobacillus/Leuconostoc/Pediococcus numbers)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Weight regain after energy restriction
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bayesian network modeling
Number of subjects: 50
Study: 24173203

Group type: EXPERIMENTAL
Intervention: Er:YAG 2940nm laser associated with amorolfine lacquer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24173271

Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 238

Group type: COMPARATOR
Intervention: Asymptomatic patients
Number of subjects: 238
Study: 24173967

Group type: EXPERIMENTAL
Intervention: Dasatinib (70 mg daily) in combination with capecitabine (850 mg/m² twice daily, days 1-14), oxaliplatin (130 mg/m² on day 1), and bevacizumab (7.5 mg/kg on day 1), every 3 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dasatinib (50 mg bid)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dasatinib (70 mg daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CapeOx/bevacizumab
Number of subjects: 22
Study: 24174627

Group type: EXPERIMENTAL
Intervention: hIL-6 plus vIL-6
Number of subjects: 21

Group type: COMPARATOR
Intervention: hIL-6 only
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: vIL-6 only
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both hIL-6 and vIL-6
Number of subjects: 21
Study: 24175592

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 82
Study: 24175721

Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine fumarate (quetiapine XR) adjunct to index antidepressant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine fumarate (quetiapine XR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24175720

Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine fumarate (quetiapine XR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24176441

Group type: EXPERIMENTAL
Intervention: New-onset atrial fibrillation (AF) > 30 s
Number of subjects: 277
Study: 24176797

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 24176798

Group type: EXPERIMENTAL
Intervention: Guaiac-based faecal occult blood test
Number of subjects: 6793

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori stool antigen test
Number of subjects: 6793

Group type: EXPERIMENTAL
Intervention: Immunochemical test
Number of subjects: 6793

Group type: EXPERIMENTAL
Intervention: H pylori antigen test
Number of subjects: 6793
Study: 24176990

Group type: EXPERIMENTAL
Intervention: GOLD 2011 classification
Number of subjects: 9219

Group type: COMPARATOR
Intervention: GOLD 2007 classification
Number of subjects: 9219

Group type: EXPERIMENTAL
Intervention: FEV1 ≥50% predicted
Number of subjects: 9219

Group type: EXPERIMENTAL
Intervention: FEV1 <50% predicted
Number of subjects: 9219
Study: 24177180

Group type: EXPERIMENTAL
Intervention: Anti-OX40 monoclonal antibody (mAb)
Number of subjects: 30
Study: 24177377

Group type: EXPERIMENTAL
Intervention: Fluticasone therapy
Number of subjects: 15
Study: 24178625

Group type: EXPERIMENTAL
Intervention: Moderate to severe OSA (apnea-hypopnea index > 15)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No to mild OSA
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Moderate to severe OSA
Number of subjects: 93
Study: 24179294

Group type: EXPERIMENTAL
Intervention: Chronic snoring
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: Pregnancy-onset snoring
Number of subjects: 1673
Study: 24180494

Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg once daily
Number of subjects: 449
Study: 24182742

Group type: EXPERIMENTAL
Intervention: travoprost with sofZia
Number of subjects: 40
Study: 24183338

Group type: EXPERIMENTAL
Intervention: Minimally invasive coronary artery bypass grafting
Number of subjects: 91
Study: 24184254

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVR) using MitraClip
Number of subjects: 141
Study: 24184736

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks until week 52
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 89
Study: 24184983

Group type: EXPERIMENTAL
Intervention: Artesunate treatment
Number of subjects: 5
Study: 24186563

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 29620

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) and age
Number of subjects: 29620
Study: 24186906

Group type: EXPERIMENTAL
Intervention: Severely immunocompromised individuals with influenza
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonimmunocompromised individuals with influenza
Number of subjects: 0
Study: 24186912

Group type: EXPERIMENTAL
Intervention: Ischemic Stroke (IS)
Number of subjects: 2979

Group type: EXPERIMENTAL
Intervention: Transient Ischemic Attack (TIA)
Number of subjects: 2979

Group type: EXPERIMENTAL
Intervention: White matter hyperintensities
Number of subjects: 2979

Group type: EXPERIMENTAL
Intervention: Old microbleeds
Number of subjects: 2979
Study: 24188056

Group type: EXPERIMENTAL
Intervention: Surgery (lobectomy and extended procedures)
Number of subjects: 3508

Group type: EXPERIMENTAL
Intervention: Radiotherapy (mostly palliative)
Number of subjects: 3508

Group type: EXPERIMENTAL
Intervention: Systemic treatment
Number of subjects: 3508

Group type: EXPERIMENTAL
Intervention: Overall healthcare resource utilization
Number of subjects: 3508
Study: 24188226

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia (MTH)
Number of subjects: 0
Study: 24188715

Group type: EXPERIMENTAL
Intervention: Endovascular repair of aortic aneurysm with patent collateral beds
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Endovascular repair of aortic aneurysm with occluded collateral beds
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Patients with immediate presentation of SCI
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Patients with occlusion of at least one collateral bed
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Patients with permanent SCI
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Patients with temporary SCI
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 1251

Group type: EXPERIMENTAL
Intervention: Recovery of patients with SCI
Number of subjects: 1251
Study: 24188875

Group type: EXPERIMENTAL
Intervention: 25 μg recombinant hCG (r-hCG)
Number of subjects: 36
Study: 24189085

Group type: EXPERIMENTAL
Intervention: 1.8 mg liraglutide
Number of subjects: 52

Group type: COMPARATOR
Intervention: Liraglutide-placebo (control)
Number of subjects: 52
Study: 24189578

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Adjustable gastric banding
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Overall WLS
Number of subjects: 242
Study: 24189773

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 2458

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 2458
Study: 24190440

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (Roux-en-Y gastric bypass or laparoscopic adjustable gastric banding)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 106
Study: 24190901

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring (ABPM) parameters including 24-hour systolic blood pressure (SBP), diastolic blood pressure (DBP), percentage of time awake with SBP ≥135 mm Hg, percentage of time asleep with SBP ≥120 mm Hg, and central aortic blood pressure
Number of subjects: 1544

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis adjusting for age, sex, body mass index, and heart rate
Number of subjects: 1544

Group type: EXPERIMENTAL
Intervention: 24-hour blood pressure monitoring
Number of subjects: 1544
Study: 24191174

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (N = 51)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (N = 51)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Wait-list control (N = 52)
Number of subjects: 154
Study: 24192652

Group type: EXPERIMENTAL
Intervention: Children with FH
Number of subjects: 196

Group type: COMPARATOR
Intervention: Unaffected siblings
Number of subjects: 196
Study: 24193798

Group type: EXPERIMENTAL
Intervention: RP-1127 (glyburide for injection) at a dose of 3 mg/d
Number of subjects: 10
Study: 24194874

Group type: EXPERIMENTAL
Intervention: Active VNS
Number of subjects: 15
Study: 24195547

Group type: EXPERIMENTAL
Intervention: Resistive index ≥ 0.80
Number of subjects: 321

Group type: COMPARATOR
Intervention: Biopsies with antibody-mediated rejection or acute tubular necrosis
Number of subjects: 321
Study: 24196401

Group type: EXPERIMENTAL
Intervention: Insulin treatment during pregnancy
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Prepregnancy obesity
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Older maternal age
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Suboptimal in-hospital breastfeeding
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Higher gestational age (only in multiparous mothers)
Number of subjects: 883
Study: 24198310

Group type: EXPERIMENTAL
Intervention: Overweight (BMI ≥25 kg/m²) in Morocco
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) in Morocco
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Overweight (BMI ≥25 kg/m²) in Tunisia
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) in Tunisia
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Coexistence of overall or central adiposity with ID in Morocco
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Coexistence of overall or central adiposity with ID in Tunisia
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Coexistence of overall or central adiposity with anemia in Morocco
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Coexistence of overall or central adiposity with anemia in Tunisia
Number of subjects: 2500
Study: 24198629

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily for 12 weeks
Number of subjects: 923

Group type: COMPARATOR
Intervention: Placebo once daily for 12 weeks
Number of subjects: 923
Study: 24200517

Group type: EXPERIMENTAL
Intervention: Automated text message based weight loss program (3-5 text messages daily for 8 weeks, including printed materials and weekly counseling calls)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Automated text message based weight loss program
Number of subjects: 20
Study: 24200875

Group type: EXPERIMENTAL
Intervention: Instrumented modified BESS
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Instrumented BESS
Number of subjects: 13

Group type: COMPARATOR
Intervention: Modified BESS
Number of subjects: 13

Group type: COMPARATOR
Intervention: BESS
Number of subjects: 13
Study: 24200998

Group type: EXPERIMENTAL
Intervention: AKN-028
Number of subjects: 0
Study: 24201015

Group type: EXPERIMENTAL
Intervention: Bevacizumab with external beam radiation (EB)
Number of subjects: 19
Study: 24201857

Group type: EXPERIMENTAL
Intervention: Single-dose IV sildenafil (0.25, 0.35, or 0.45 mg/kg over 20 min)
Number of subjects: 9
Study: 24203067

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism (SNP) rs26125 (PPARGC1B)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism (SNP) rs4759277 (LRP1)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism (SNP) rs184003 (AGER)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism (SNP) rs7301876 (ABCC9)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism (SNP) rs290481 (TCF7L2)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Single nucleotide polymorphism (SNP) rs12691 (CEBPA)
Number of subjects: 450
Study: 24203510

Group type: EXPERIMENTAL
Intervention: Rilpivirine coadministration (Days 1 to 11)
Number of subjects: 13
Study: 24204746

Group type: EXPERIMENTAL
Intervention: HSVTK-tCD34 suicide gene modified donor T cells
Number of subjects: 3
Study: 24205333

Group type: EXPERIMENTAL
Intervention: High fat overfeeding (+1250 kCal/day, 45% fat)
Number of subjects: 40
Study: 24205345

Group type: EXPERIMENTAL
Intervention: Transfer of care
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Did not transfer care
Number of subjects: 393
Study: 24206649

Group type: EXPERIMENTAL
Intervention: Real-time PCR screening and species identification assays in a mobile laboratory
Number of subjects: 5000
Study: 24206748

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI) video PVCS
Number of subjects: 30

Group type: COMPARATOR
Intervention: White-light imaging
Number of subjects: 30
Study: 24210084

Group type: EXPERIMENTAL
Intervention: ADT plus docetaxel
Number of subjects: 385

Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 385
Study: 24210146

Group type: EXPERIMENTAL
Intervention: In situ hypothermic perfusion with retrograde outflow during right hemihepatectomy
Number of subjects: 0
Study: 24210779

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) with radiofrequency ablation
Number of subjects: 153
Study: 24211066

Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of autologous bone-marrow derived mesenchymal stromal cells (BMMSCs)
Number of subjects: 31
Study: 24214373

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg single oral dose
Number of subjects: 20
Study: 24214901

Group type: EXPERIMENTAL
Intervention: Mechanical Circulatory Support (MCS)
Number of subjects: 3363
Study: 24214905

Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g intravenously before surgery
Number of subjects: 16
Study: 24215775

Group type: EXPERIMENTAL
Intervention: Collaborative care team support model
Number of subjects: 1406

Group type: EXPERIMENTAL
Intervention: Technology-facilitated depression care model
Number of subjects: 1406

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1406
Study: 24218035

Group type: EXPERIMENTAL
Intervention: Sorafenib (So) treatment
Number of subjects: 45
Study: 24218170

Group type: EXPERIMENTAL
Intervention: Bone marrow biopsies from patients with CLI
Number of subjects: 33

Group type: COMPARATOR
Intervention: Bone marrow biopsies from controls
Number of subjects: 33
Study: 24218191

Group type: EXPERIMENTAL
Intervention: Untreated preoperative depression
Number of subjects: 107
Study: 24218513

Group type: EXPERIMENTAL
Intervention: Imiquimod ointment and subcutaneous vaccinations (100 μg IDO5 peptide, sequence ALLEIASCL, formulated in 900 μL Montanide)
Number of subjects: 15
Study: 24219045

Group type: EXPERIMENTAL
Intervention: Bivalirudin (BVR)
Number of subjects: 0
Study: 24219412

Group type: EXPERIMENTAL
Intervention: Preclinical COPD
Number of subjects: 60

Group type: COMPARATOR
Intervention: Smoking control subjects
Number of subjects: 60

Group type: COMPARATOR
Intervention: Never-smoking control subjects
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preclinical COPD and smoking control subjects
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Physical inactivity and smoking
Number of subjects: 60
Study: 24220233

Group type: EXPERIMENTAL
Intervention: Internet-based patient-provider communication service (IPPC)
Number of subjects: 22
Study: 24220277

Group type: EXPERIMENTAL
Intervention: CBT intervention with weekly therapist contact
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CBT intervention without therapist contact
Number of subjects: 150

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 150
Study: 24220559

Group type: EXPERIMENTAL
Intervention: R-GCVP (rituximab, gemcitabine, cyclophosphamide, vincristine, and prednisolone)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: R-GCVP
Number of subjects: 61
Study: 24220703

Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone vaginally daily for 3 months
Number of subjects: 33
Study: 24221839

Group type: EXPERIMENTAL
Intervention: Life chaos increase (measured by an instrument)
Number of subjects: 406

Group type: COMPARATOR
Intervention: CVD-medication nonadherence
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Life chaos factors
Number of subjects: 406
Study: 24222348

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 3865

Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 3865

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 3865
Study: 24222969

Group type: EXPERIMENTAL
Intervention: Standardized fecal microbiota transplantation (FMT)
Number of subjects: 1
Study: 24223036

Group type: EXPERIMENTAL
Intervention: Integrated cognitive behavioral therapy
Number of subjects: 205

Group type: COMPARATOR
Intervention: 12-Step interventions
Number of subjects: 205
Study: 24224021

Group type: EXPERIMENTAL
Intervention: ED visit/hospitalization for painful vaso-occlusive crises (VOCs)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Higher tricuspid regurgitatant jet velocity (TRV)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Elevated ferritin
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Lower glomerular filtration rate
Number of subjects: 264